Actively Recruiting
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Led by Chinese PLA General Hospital · Updated on 2026-03-20
200
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
C
Chinese PLA General Hospital
Lead Sponsor
T
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.
CONDITIONS
Official Title
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute myeloid leukemia and eligible for allogeneic hematopoietic stem cell transplantation in first complete remission
- Have an HLA-matched sibling donor, haploidentical donor, or at least 8/10 HLA-matched unrelated donor
- Age between 12 and 64 years old
- Liver function tests: ALT and AST less than or equal to 2.5 times the upper normal limit, bilirubin less than or equal to 2 times the upper normal limit
- Kidney function: creatinine within normal limits
- No uncontrolled infections or serious mental or psychological disorders
- Signed informed consent form
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia (M3)
- Either donor or recipient is pregnant
- Presence of mental illness or other conditions preventing protocol adherence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
L
Li-ping Dou, Dr.
CONTACT
D
Dai-hong Liu, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here